BioCentury | May 13, 2002
Company News

Bioption AB, International AIDS Vaccine Initiative deal

Bioption partnered with the initiative to develop an HIV/AIDS vaccine. The initiative will finance and coordinate research based on SFV alphavirus replicon technology from the Karolinska Institute (Stockholm, Sweden). Bioption AB , Stockholm, Sweden International AIDS...
BioCentury | Apr 1, 2002
Emerging Company Profile

Replicon: Rethinking poliovirus

...this tropism for CNS tissue, with its inherent ability to cross the blood-brain barrier, that Replicon Technologies Inc....
BioCentury | Apr 1, 2002
Emerging Company Profile

Corporate Profile

Replicon Technologies Inc. Birmingham, Ala. Technology: Poliovirus replicons Disease focus: Brain and CNS cancers, CNS disorders Clinical status: Preclinical Founded: 1997 by Donna Porter, David Ansardi and Casey Morrow Corporate partners: NA University collaborators: NA...
BioCentury | Jan 14, 2002
Company News

Replicon Technologies board of directors update

Replicon Technologies Inc., Danville, Calif. Business: Cancer Appointed: Lyle Hohnke, partner at Tullis-Dickerson & Co. Inc. WIR Staff cancer...
BioCentury | Jan 14, 2002
Company News

Replicon Technologies management update

Replicon Technologies Inc., Danville, Calif. Business: Cancer Hired: Anthony Maida as president and CEO, formerly chairman and CEO at BioConsul Drug Development Corp. WIR Staff cancer...
BioCentury | Dec 10, 2001
Clinical News

Replicon Technologies preclinical data

...both at the primary tumor site as well as at metastatic sites within the brain. Replicon Technologies Inc....
Items per page:
1 - 6 of 6
BioCentury | May 13, 2002
Company News

Bioption AB, International AIDS Vaccine Initiative deal

Bioption partnered with the initiative to develop an HIV/AIDS vaccine. The initiative will finance and coordinate research based on SFV alphavirus replicon technology from the Karolinska Institute (Stockholm, Sweden). Bioption AB , Stockholm, Sweden International AIDS...
BioCentury | Apr 1, 2002
Emerging Company Profile

Replicon: Rethinking poliovirus

...this tropism for CNS tissue, with its inherent ability to cross the blood-brain barrier, that Replicon Technologies Inc....
BioCentury | Apr 1, 2002
Emerging Company Profile

Corporate Profile

Replicon Technologies Inc. Birmingham, Ala. Technology: Poliovirus replicons Disease focus: Brain and CNS cancers, CNS disorders Clinical status: Preclinical Founded: 1997 by Donna Porter, David Ansardi and Casey Morrow Corporate partners: NA University collaborators: NA...
BioCentury | Jan 14, 2002
Company News

Replicon Technologies board of directors update

Replicon Technologies Inc., Danville, Calif. Business: Cancer Appointed: Lyle Hohnke, partner at Tullis-Dickerson & Co. Inc. WIR Staff cancer...
BioCentury | Jan 14, 2002
Company News

Replicon Technologies management update

Replicon Technologies Inc., Danville, Calif. Business: Cancer Hired: Anthony Maida as president and CEO, formerly chairman and CEO at BioConsul Drug Development Corp. WIR Staff cancer...
BioCentury | Dec 10, 2001
Clinical News

Replicon Technologies preclinical data

...both at the primary tumor site as well as at metastatic sites within the brain. Replicon Technologies Inc....
Items per page:
1 - 6 of 6